Stock of EpiPen Jr has run out in Australia

Stock of EpiPen Jr has run out in Australia. TGA is working with Mylan to confirm arrangements for supply of the new batch.

In light of this critical development, ASCIA (the Australasian Society of Clinical Immunology and Allergy) recommends that all remaining stock in pharmacies should be provided to newly diagnosed infants and children weighing 7.5-20kg, and those who have used their EpiPen® Jr and have no other dose available.

ASCIA requests that schools and early childhood education/care (ECEC) centres take into account the current supply issues, by not requesting additional EpiPen® Jr devices to be brought to the school or ECEC centre for each child at risk of anaphylaxis, and to limit the replacement of general use devices at this time. 

Where there is no alternative available ASCIA advises schools and ECEC that it may be necessary to accept recently expired EpiPen autoinjectors during nation-wide shortages. Please see more information at

Parents should be able to bring EpiPen® Jr devices to and from school each day with the child.

Parents and carers requiring documentation for schools and ECEC during the out of stock period can use this ASCIA document: ASCIA EpiPen Jr Out of Stock ECEC December 2019.

Emergency treatment if you do not have an EpiPen

  • ASCIA recommends calling 000 (Australia) or 111 (New Zealand) if a person has any signs of anaphylaxis (severe allergic reaction) after using an EpiPen (in date or expired) if available.
  • If there is no access to adrenaline call an ambulance early if there are signs of an allergic reaction and you are uncertain if there are signs of anaphylaxis.
  • Always follow the ASCIA Action Plan. Keep the person with allergy lying flat or sitting on the ground/lap with legs outstretched in front of them (not dangling).
  • The person having an allergic reaction should not stand or walk as this can cause a sudden drop in blood pressure. Babies/children should not be held upright.

The Therapeutic Goods Administration (TGA) will provide additional information as it becomes available. The TGA is part of the Health Products Regulation Group (HPRG) in the Australian Government Dept of Health.

People requiring an EpiPen Jr 150 mcg adrenaline (epinephrine) auto-injector should contact their local pharmacy.

The risk from not having adrenaline available to treat anaphylaxis is high and people with responsibility for potentially affected children should familiarise themselves with the full range of advice provided by ASCIA.